Zhen Wang

Zhen Wang

Auto-generated profile, based on publicly available information

Zhen Wang

Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2020 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
SWSongyun Wang
Songyun Wang
WMWeilun Meng
Weilun Meng
ZRZhongyuan Ren
Zhongyuan Ren
BLBinxun Li
Binxun Li
TZTongjian Zhu
Tongjian Zhu
HJHong Jiang
Hong Jiang
Non-invasive ultrasonic neural modulation (UNM), a non-invasive technique with enhanced spatial focus compared to conventional electrical neural modulation, has attracted much attention in recent decades and might become the mainstream regimen for neurological disorders. However, as ultrasonic bioeffects and its adjustments are still unclear, it remains difficult to be extensively applied for therapeutic purpose, much less in the setting of human skull. Hence to comprehensively understand the way ultrasound exerts bioeffects, we explored UNM from a basic perspective by illustrating the parameter settings and the underlying mechanisms. In addition, although the spatial resolution and precision of UNM are considerable, UNM is relatively non-specific to tissue or cell type and shows very low specificity at the molecular level. Surprisingly, Ibsen et al. (2015) first proposed the concept of sonogenetics, which combined UNM and mechanosensitive (MS) channel protein. This emerging approach is a valuable improvement, as it may markedly increase the precision and spatial resolution of UNM. It seemed to be an inspiring tool with high accuracy and specificity, however, little information about sonogenetics is currently available. Thus, in order to provide an overview of sonogenetics and prompt the researches on UNM, we summarized the potential mechanisms from a molecular level.

1 July 2019 in Stem Cell Research
Verified
Journal Article
Open access
ZWZhen Wang
Zhen Wang
LWLipeng Wang
Lipeng Wang
WLWenling Liu
Wenling Liu
DHDayi Hu
Dayi Hu
YGYuanfeng Gao
Yuanfeng Gao
CLCuilan Li
Cuilan Li
To establish a KCNQ1 mutant-specific induced pluripotent stem cell (iPSC) model of a Chinese inherited long QT syndrome (LQTS) patient and to explore the pathogenesis of KCNQ1 mutations. (1) Two patient-specific iPSC lines from the proband were obtained. (2) The experiments produced spontaneously beating cardiomyocytes (CMs) from patient iPSCs. Splicing mutation c. 605-2A > G in iPSC-derived cardiomyocytes (iPSC-CMs) resulted in the skipping of exon 4, exons 3-4, or exons 3-6 in KCNQ1 transcription what was observed in the patient's peripheral leukocytes. (3) Action potential duration (APD) at 50% and 90% repolarization (APD50 and APD90) of the patient's iPSC-derived ventricular-like-CMs was significantly longer than that of the control. Moreover, early after depolarization (EAD) and coupled beats were observed only in L1-iPSC-CMs. (4) A c.815G > A corrected iPSC line was obtained by using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) system. (1) Cardiomyocytes with spontaneous pulsation were successfully differentiated from LQTS patient-specific iPSC lines. (2) For KCNQ1 splicing mutations, there is a chance that splicing patterns in peripheral leukocytes are similar to that in patient iPSC-CMs. (3) The truncated KCNQ1 proteins induced by such splicing mutation might cause Iks decrease, which in turn produced APD prolongation and triggered activities. (4) Our data showed that CRISPR-Cas9 system could be used to rescue the LQTS-related mutations.

7 July 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
ZWZhen Wang
Zhen Wang
YLYiwei Lai
Yiwei Lai
YWYufeng Wang
Yufeng Wang
JWJue Wang
Jue Wang
CJChao Jiang
Chao Jiang
CMChangsheng Ma
Changsheng Ma
After radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF), the effect of very-early (within 48 h) symptomatic recurrence (VESR) on late (after 3 months of RFCA) recurrence (LR) has been seldomly reported. We aimed to explore the relationship between VESR and LR among post-RFCA patients. This was a single-centre prospective cohort study that enrolled 6887 AF patients who received the first RFCA procedure from June 2018 to December 2021 at Beijing Anzhen Hospital. Patients were divided into four groups based on VESR and early (from 48 h to 3 months after RFCA) recurrence (ER): Group A (no VESR, no ER); Group B (VESR but no ER); Group C (ER but no VESR); and Group D (both VESR and ER). Three hundred and thirty (4.79%) patients experienced VESR (Groups B and D). With an average follow-up of 14.7 months after grouping, the Kaplan–Meier curve showed that LR risk in VESR patients was higher than in other patients (log-rank, P < 0.001), and the difference was significant in both paroxysmal (log-rank, P < 0.001) and persistent (log-rank, P < 0.001) AF patients (P for interaction = 0.118). In multivariate analysis, Groups B, C, and D were associated with a 2.161-, 5.409-, and 7.401-fold increase in the risk of LR, respectively. What is more, compared with Group A, VESR-atrial tachycardia and VESR-AF were related to a 3.467- and 5.564-fold LR risk, respectively. In VESR patients, classification based on ER and VESR modes improved the prediction potential of LR risk. Very-early symptomatic recurrence is associated with an increased risk of LR.

29 January 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
JLJiaju Li
Jiaju Li
YLYiwei Lai
Yiwei Lai
CJChao Jiang
Chao Jiang
MLMingxiao Li
Mingxiao Li
ZYZejun Yang
Zejun Yang
JDJianzeng Dong
Jianzeng Dong
Aims: Fibroblast growth factor 23 (FGF23) has been implicated in the occurrence of atrial fibrillation (AF), but its prognostic value in AF patients remains unclear. Methods and results: A total of 35 197 AF patients with available follow-up data (3.56, 0.47–8.92 years) from the UK Biobank were included. Clinical association between serum FGF23 and AF-related outcomes including mortality, heart failure (HF), ischaemic stroke, and dementia were analysed using multivariable Cox regression. In those passed quality control for array sequencing, polygenic score for FGF23 (PGSFGF23) was calculated as genetic instrument, and the association between PGSFGF23 and the occurrence of endpoints after first AF diagnosis were further explored. In 886 patients who diagnosed AF at or prior to the enrolment, elevated serum FGF23 levels were significantly associated with an increased risk of all-cause (37% increase per standard deviation) and cardiovascular (40% increase per standard deviation) mortality and HF (43% increase per standard deviation). A total of 35 197 patients were available for genetic array sequencing data. Using polygenic score including seven independent SNPs reaching genome-wide significance threshold, genetic association analysis indicated that increased PGSFGF23 is associated with reduced risk of HF but increased risk of all-cause mortality and ischaemic stroke. Conclusion: Our findings suggest that FGF23 is a potential biomarker for accessing AF-related outcomes. The paradoxical association between genetic FGF23 and serum FGF23 level highlights the need for further investigation to elucidate the underlying mechanisms.

16 October 2026 in JACC
Verified
Journal Article
Closed access
ZZZixu Zhao
Zixu Zhao
MLMingxiao Li
Mingxiao Li
ZWZhixian Wang
Zhixian Wang
TJTiannan Jiang
Tiannan Jiang
CWChaohui Wang
Chaohui Wang
CMChangsheng Ma
Changsheng Ma

6 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
LRLan Ren
Lan Ren
XPXiaodong Peng
Xiaodong Peng
SLSitong Li
Sitong Li
JWJue Wang
Jue Wang
JZJingrui Zhang
Jingrui Zhang
CMChangsheng Ma
Changsheng Ma
Background: Despite the growing use of catheter ablation for atrial fibrillation, large‐scale studies assessing the efficacy and safety of oral anticoagulation (OAC) after ablation, particularly in patients with high stroke risk, remain limited. Methods: This prospective study enrolled consecutive patients from the China‐AF (China Atrial Fibrillation) registry between August 2011 and June 2022. Stroke risk was stratified by CHA 2 DS 2 ‐VA score as low (0–1), intermediate (2), or high (≥3). The study end points were thromboembolism (ischemic stroke or systemic embolism), and bleeding (International Society on Thrombosis and Hemostasis major bleeding and clinically relevant non‐major bleeding). A 6‐month landmark analysis was applied to evaluate the association of OAC with end points using incidence rates and Cox models. Results: Among 13 669 patients (median follow‐up, 4.0 years), 2637 continued and 11 032 discontinued OAC at the 6‐month landmark. OAC was not associated with reduced thromboembolism risk across low‐ (adjusted hazard ratio [aHR], 1.11 [95% CI, 0.70–1.77]; P =0.649), intermediate‐ (aHR, 0.64 [95% CI, 0.36–1.16]; P =0.141) or high‐stroke risk patients (aHR, 1.05 [95% CI, 0.74–1.48]; P =0.801). In contrast, continued OAC was associated with higher bleeding risk, including clinically relevant non‐major bleeding across stroke risk strata, and International Society on Thrombosis and Hemostasis major bleeding among high‐risk patients (aHR, 2.32 [95% CI, 1.19–4.50]; P =0.013). These results were consistent across subgroups and sensitivity analyses. Conclusions: In this large, real‐world cohort of patients with atrial fibrillation undergoing catheter ablation, continued OAC was not associated with lower thromboembolic risk, but with higher major bleeding risk among patients with CHA 2 DS 2 ‐VA scores ≥3. These findings support individualized post‐ablation anticoagulation strategies and warrant future investigation. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT06987825.